Highlights from the literature

ABSTRACT

The authors highlight that this study provides the first direct evidence of the prevention of cervical cancer using a bivalent HPV vaccine. In a was a two-part clinical trial which is an open-label, dose-finding study using 50 L3 larvae suspended in water and a randomised, double-blind, placebo-controlled, challenge study, in which participants were randomly assigned 21 to the vaccine group or placebo group. Significant changes in eosinophil count, IgG response and cytokine and peripheral blood mononuclear cells were noted and significantly fewer larvae per g of faeces were recovered in the vaccine group than in the placebo group after challenge (median larvae per g 0·8 [IQR 0.00 to 3.91] vs 10·2 [5·1 to 18·1];p=0.014).